FDA fires off a warning on rare cases involving death, adverse liver events linked to misuse of 3 big hep C drugs
Just as one probably errant drug safety rumor was being debunked at Vertex, the FDA triggered a real alarm on a trio of prominent hep C drugs now linked with a lethal liver reaction.
AbbVie’s Mavyret, Merck’s now deeply discounted drug Zepatier and Gilead’s Vosevi were involved in 63 cases of liver decompensation — incidents of liver dysfunction — which includes some deaths, according to the FDA. Most suffered from significant liver impairment and should never have been prescribed the drug to begin with. And the agency wants to find out if there are more.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.